Ironwood Pharmaceuticals, Inc.

NASDAQ:IRWD

Drug Manufacturers - Specialty & Generic

Healthcare
$4.78 +0.14%

+$0.01 today

Market cap
$791.33M
Beta
0.24
P/E (TTM)
5.6
EPS (TTM)
$0.63
52W Low $0.66High $5.78

Volume 2.22M

Average 2.35M

IRWD EBITDA Margin

EBITDA as a percentage of revenue.

Ironwood Pharmaceuticals, Inc.NASDAQ: IRWD

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin widens to 70.2%

EBITDA Margin was 70.2% in Q1 FY2026, up 94.7 pp from a year earlier. On a trailing-twelve-month basis it was 57.3%, up 32.9 pp year over year. Over 3 fiscal years it narrowed by 28.3 pp.

Context

  • EBITDA Margin widened in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 2 analysts of 81.6% for the fiscal year ending Dec 2026, up from 35.3% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
70.2%+51.7 pp QoQ
Last fiscal yearDec 2025
35.3%+7.5 pp YoY
LTMMar 2026
57.3%+32.9 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+94.7 pp+27.8 pp-66.9 pp
1 year+7.5 pp+46.2 pp+38.7 pp
3 years-28.3 pp+54.5 pp+82.8 pp
5 years+83.0 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
35.3%
Year-over-year change
+7.5pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How IRWD compares with its peers on the latest reported figures

  • IRWD's LTM Mar 2026 EBITDA Margin of 57.3% is the highest of the 3 companies compared; the peer median is -157.7%.
  • Its year-over-year change of +32.9 pp is the highest of 2, against a peer median of +1.8 pp.
  • Over three fiscal years its change of -28.3 pp compares with a peer median of +109.8 pp.
IRWD Competitors Peer median
EBITDA Margin for IRWD and competitors
Company Period LTM level YoY 3-year change
IRWDIronwood Pharmaceuticals, Inc.LTM Mar 202657.3% +32.9 pp-28.3 pp
ARDXArdelyx, Inc.LTM Mar 2026-6.0% +1.8 pp+109.8 pp
SYRESpyre Therapeutics, Inc.LTM Sep 2026-309.5% ——
Peer median (excluding IRWD) -157.7%+1.8 pp+109.8 pp

Competitors are the stored peer set for IRWD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue413.75M410.6M442.74M351.41M296.15M
Cost of Revenue70.41M1.42M6.15M7.55M0
Gross Profit343.35M409.18M436.59M343.86M296.15M
Gross Margin83.0%99.7%98.6%97.9%100.0%
Research & Development70.41M44.27M116.09M111.42M95.14M
Selling, General & Admin0115.99M0082.26M
Operating Expenses111.09M158.84M1.38B250.73M177.39M
Depreciation & Amortization1.52M1.42M1.58M2.01M1.88M
EBITDA233.74M261.44M197.41M97.73M104.65M
EBITDA Margin56.5%63.7%44.6%27.8%35.3%
Operating Income232.26M250.34M(945.43M)93.12M118.76M
Operating Margin56.1%61.0%-213.5%26.5%40.1%
Interest Income726K9.5M18.97M4.47M4.08M
Interest Expense31.15M7.6M21.63M33.03M32.75M
Other Income / Expenses(31.6M)2.09M(2.64M)(27.93M)(48.73M)
Income Before Tax200.66M252.42M(948.07M)65.2M70.03M
Pre-Tax Margin48.5%61.5%-214.1%18.6%23.6%
Income Tax Expense(327.79M)77.36M83.49M64.32M46.01M
Net Income528.45M175.07M(1B)880K24.02M
Net Margin127.7%42.6%-226.4%0.3%8.1%
EPS (Basic)3.261.13(6.45)0.010.15
EPS (Diluted)3.210.96(6.45)0.010.15
Weighted Avg Shares162.25M154.37M155.44M159.08M162.22M
Weighted Avg Shares (Diluted)164.42M186.31M155.44M160.08M177.76M

Ironwood Pharmaceuticals, Inc.

NASDAQ:IRWD

Intrinsic Alpha fair value

Locked

Current Price

$4.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.